Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA 6-512 (trans-resveratrol) multiple-dose study in healthy volunteers
NCT03093389Phase 1Completed
- Sponsor
- BIAL
- Start
- May 2005
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of resveratrol in Parkinson's disease (PD) (4 cohorts), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started May 2005; status: completed.
02
Drugs
resveratrol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03093389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093389.